1.99
price up icon13.07%   0.23
after-market Handel nachbörslich: 1.99
loading
Schlusskurs vom Vortag:
$1.76
Offen:
$1.78
24-Stunden-Volumen:
73,002
Relative Volume:
2.33
Marktkapitalisierung:
$117.19M
Einnahmen:
$18.11M
Nettoeinkommen (Verlust:
$-18.95M
KGV:
-4.5486
EPS:
-0.4375
Netto-Cashflow:
-
1W Leistung:
+2.58%
1M Leistung:
+25.16%
6M Leistung:
-3.40%
1J Leistung:
-33.44%
1-Tages-Spanne:
Value
$1.78
$2.045
1-Wochen-Bereich:
Value
$1.73
$2.13
52-Wochen-Spanne:
Value
$1.325
$3.5807

Adagene Inc Adr Stock (ADAG) Company Profile

Name
Firmenname
Adagene Inc Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
138
Name
Twitter
Name
Nächster Verdiensttermin
2024-03-28
Name
Neueste SEC-Einreichungen
Name
ADAG's Discussions on Twitter

Vergleichen Sie ADAG mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ADAG
Adagene Inc Adr
1.99 92.10M 18.11M -18.95M 0 -0.4375
Biotechnology icon
ONC
Beone Medicines Ltd Adr
255.86 26.69B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.50 114.81B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.232 41.83M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
84.34 6.60B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
493.22 65.36B 14.09B 4.50B 2.96B 39.28

Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-01-31 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-06-25 Eingeleitet China Renaissance Buy
2021-03-08 Eingeleitet Goldman Buy
2021-03-08 Eingeleitet Jefferies Buy
2021-03-08 Eingeleitet Morgan Stanley Overweight

Adagene Inc Adr Aktie (ADAG) Neueste Nachrichten

pulisher
Jun 03, 2025

Is McKesson (MCK) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Jun 03, 2025
pulisher
Jun 02, 2025

Adagene Announces Participation At Leerink’s Global Healthcare Conference 2025 - Bernama

Jun 02, 2025
pulisher
May 31, 2025

Adagene Inc. (NASDAQ:ADAG) Sees Significant Growth in Short Interest - Defense World

May 31, 2025
pulisher
May 27, 2025

Adagene to Present at Jefferies Global Healthcare Conference 2025 - The Manila Times

May 27, 2025
pulisher
May 27, 2025

Adagene Inc. to Participate in Jefferies Global Healthcare Conference 2025 with Fireside Chat and Investor Meetings - Nasdaq

May 27, 2025
pulisher
May 27, 2025

Exclusive: Adagene Leadership Reveals Latest Antibody Therapeutic Strategy at Major Jefferies Conference - Stock Titan

May 27, 2025
pulisher
May 23, 2025

Adagene (NASDAQ:ADAG) Trading Down 2.1% – Here’s Why - Defense World

May 23, 2025
pulisher
May 22, 2025

Adagene Reports Promising ADG126 Study Results at ASCO - TipRanks

May 22, 2025
pulisher
May 22, 2025

Adagene Announces Updated Data from Phase 1b/2 Study of - GlobeNewswire

May 22, 2025
pulisher
May 22, 2025

New Clinical Data: Adagene's ADG126 Achieves Breakthrough 29% Response Rate in Hard-to-Treat Colorectal Cancer - Stock Titan

May 22, 2025
pulisher
Apr 30, 2025

Adagene Inc. (NASDAQ:ADAG) Short Interest Update - Defense World

Apr 30, 2025
pulisher
Apr 28, 2025

Adagene Appoints John Maraganore, Ph.D. as Executive Advisor - GlobeNewswire

Apr 28, 2025
pulisher
Apr 28, 2025

Biotech Pioneer Behind $25B Alnylam Success Story Takes Strategic Role at Adagene's Cancer Drug Mission - Stock Titan

Apr 28, 2025
pulisher
Apr 23, 2025

Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times

Apr 23, 2025
pulisher
Apr 23, 2025

Adagene Inc. Announces Poster Presentation on ADG126 at ASCO 2025 Conference - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Adagene Announces Upcoming Poster Presentation on Masked - GlobeNewswire

Apr 23, 2025
pulisher
Apr 07, 2025

Adagene to Present at Stifel's 2025 Virtual Targeted Oncology Forum - The Manila Times

Apr 07, 2025
pulisher
Apr 07, 2025

Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum - GlobeNewswire

Apr 07, 2025
pulisher
Apr 07, 2025

Adagene Reveals New Oncology Strategy: CEO Set for Major Investor Presentation - Stock Titan

Apr 07, 2025
pulisher
Apr 07, 2025

FY2025 Earnings Estimate for Adagene Issued By HC Wainwright - Defense World

Apr 07, 2025
pulisher
Apr 05, 2025

Adagene (NASDAQ:ADAG) Earns “Buy” Rating from HC Wainwright - Defense World

Apr 05, 2025
pulisher
Mar 27, 2025

Adagene stock hits 52-week low at $1.62 amid market challenges By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Adagene stock hits 52-week low at $1.62 amid market challenges - Investing.com

Mar 27, 2025
pulisher
Mar 25, 2025

Adagene (ADAG) to Release Quarterly Earnings on Thursday - Defense World

Mar 25, 2025
pulisher
Mar 24, 2025

Adagene Reports 33% Overall Response Rate in Phase 2 Expansion of Muzastotug for MSS CRC, Highlights Financial Position and Future Milestones - Nasdaq

Mar 24, 2025
pulisher
Mar 24, 2025

Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

Adagene Reveals Breakthrough Cancer Trial Results in 2024 Financial Update - Stock Titan

Mar 24, 2025
pulisher
Mar 14, 2025

Adagene Inc. (NASDAQ:ADAG) Short Interest Down 55.9% in February - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit - GlobeNewswire

Mar 13, 2025
pulisher
Mar 13, 2025

Adagene Inc. to Present ADG126 SAFEbody® Data at 11th Annual Immuno-Oncology 360⁰ Summit in Boston - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Adagene's Revolutionary Cancer Treatment Targets CTLA-4: Key Presentation Coming to IO360 Summit - StockTitan

Mar 13, 2025
pulisher
Mar 12, 2025

Adagene to Present at the Leerink Partners Global Biopharma Conference 2024, Business Wires News - AsiaOne

Mar 12, 2025
pulisher
Mar 07, 2025

Adagene to Present at Leerink’s Global Healthcare Conference 2025 - GlobeNewswire

Mar 07, 2025
pulisher
Mar 06, 2025

Adagene to Present at Leerink's Global Healthcare Conference 2025 - The Manila Times

Mar 06, 2025
pulisher
Mar 06, 2025

Can Adagene's CEO Reveal New Strategic Plans at Upcoming Leerink Conference? - StockTitan

Mar 06, 2025
pulisher
Feb 27, 2025

Adagene Inc. to Initiate Phase 2 Trial of ADG126 for Colorectal Cancer with Enrollment Starting in April 2025 - Nasdaq

Feb 27, 2025
pulisher
Feb 27, 2025

Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer - GlobeNewswire

Feb 27, 2025
pulisher
Feb 27, 2025

Could This New Colorectal Cancer Trial Change Pre-Surgery Treatment? Adagene Tests ADG126 - StockTitan

Feb 27, 2025
pulisher
Feb 23, 2025

Head to Head Analysis: Rafael (NYSE:RFL) versus Adagene (NASDAQ:ADAG) - Defense World

Feb 23, 2025
pulisher
Feb 16, 2025

Short Interest in Adagene Inc. (NASDAQ:ADAG) Declines By 50.2% - MarketBeat

Feb 16, 2025
pulisher
Feb 13, 2025

Head to Head Survey: Adagene (NASDAQ:ADAG) and Corvus Pharmaceuticals (NASDAQ:CRVS) - Defense World

Feb 13, 2025
pulisher
Feb 04, 2025

Morgan Stanley Downgrades Adagene (NASDAQ:ADAG) to Equal Weight - MarketBeat

Feb 04, 2025
pulisher
Feb 04, 2025

Adagene Inc. (NASDAQ:ADAG) Sees Large Increase in Short Interest - MarketBeat

Feb 04, 2025
pulisher
Feb 03, 2025

Adagene (NASDAQ:ADAG) Cut to “Equal Weight” at Morgan Stanley - Defense World

Feb 03, 2025
pulisher
Feb 01, 2025

FY2024 Earnings Estimate for Adagene Issued By HC Wainwright - MarketBeat

Feb 01, 2025
pulisher
Jan 31, 2025

HC Wainwright Estimates Adagene FY2029 Earnings - MarketBeat

Jan 31, 2025

Finanzdaten der Adagene Inc Adr-Aktie (ADAG)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.15
price up icon 0.00%
$585.93
price up icon 0.92%
$300.83
price down icon 2.33%
$38.11
price up icon 4.30%
$4.73
price down icon 1.69%
$493.22
price up icon 2.10%
Kapitalisierung:     |  Volumen (24h):